GL-0719

Phase 1Small molecule

GGliknik Inc.

GL-0719 is one of 3 small molecule programs targeting Cold Agglutinin Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cold Agglutinin DiseaseRecruiting

Cold Agglutinin DiseasePhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Cold Agglutinin Disease

#DrugCompanyPhaseTrials

Tazverik

EEpizyme, Inc.

Phase 3

1 2

Brukinsa

BBeOne Medicines

Phase 2

1 3

GL-0719

GGliknik Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cold Agglutinin Disease1 trial

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease

Recruiting·GGliknik Inc.·Phase 1·NCT05318534·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GL-0719. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GL-0719 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GL-0719. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gliknik Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGliknik Inc.

GL-0719

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cold Agglutinin Disease1 trial

References

Drug Info

Quick Facts

Related News